Business
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"Anticipates commencing pivotal pharmacokinetic (PK) trial for AQST-109 (epinephrine sublingual film) in second half of 2023 Anticipates receipt in the coming months of FDA response to request for Libervant™ (diazepam) Buccal Film accelerated market access Expects preliminary unaudited cash and cash equivalents of approximately $27 million as of December 31, 2022 WARREN, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and outlined key 2023 objectives. In addition, Aquestive’s Chief Executive Officer, Daniel Barber, and Chief Financial Officer, Ernie Toth, will host investor meetings from January 9 to 11, 2023 in San Francisco, concurrent with the 41st Annual J. P. Morgan Healthcare Conference. “In 2023, we plan to focus our resources on the following key initiatives: (1) advancing AQST-109 into a pivotal PK study, (2) continuing to work with the FDA to potentially accelerate the market access for Libervant, (3) exploring new capabilities for our manufacturing business, (4) continuing to expand our base of strategic collaborations with other companies, and (5) strengthening our balance sheet,” remarked Mr. Barber. “We are thankful for the collaborations that we have forged with a variety of global companies, including Indivior Inc., Zambon S.p.A., Otter Pharmaceuticals, LLC (a subsidiary of Assertio Holdings, Inc. [“Assertio”]), Mitsubishi Tanabe Pharma America, Inc., Atnahs Pharma UK Limited (Pharmanovia), Haisco Pharmaceutical Group Co., Ltd., and Hypera S.A. It is worth highlighting that the majority of these collaborations were entered into over the last 24 months. We look forward to securing possible additional collaborations in 2023 as we continue to prioritize our alliance strategies to bringing innovative and, in some cases, life-saving medications to patients.” “This is a pivotal year for Aquestive as we seek to build upon our momentum from the second half of 2022. We have an experienced team that has not only driven multiple FDA approvals, but has also excelled at collaborating with leading life sciences companies. We will be focused on ...